Opko Health Inc's Customers Performance

Name: Opko Health Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

OPK

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


OPK's Source of Revenues		During the corresponding time, Opko Health Inc recorded a revenue increase by 4.32 % year on year, sequentially revenue grew by 31.71 %. While revenue at the Opko Health Inc 's corporate clients • List of OPK Customers

for the same period Opko Health Inc recorded revenue increase by 4.32 % year on year, sequentially revenue grew by 31.71 %.

• List of OPK Customers

Opko Health Inc's Business Units


Service	44.13 %	of total Revenue
Product	23.26 %	of total Revenue
Transfer of Intellectual Property and Other	36.71 %	of total Revenue
Rayaldee	7.83 %	of total Revenue
Intellectual Property and Other	2.51 %	of total Revenue
MEXICO	4.24 %	of total Revenue
US	51.05 %	of total Revenue
IE	5.92 %	of total Revenue
CL	9.09 %	of total Revenue
ES	4.92 %	of total Revenue
Pharmaceutical Transfer of Intellectual Property and Other	8.54 %	of total Revenue
Self-Pay Service	1.43 %	of total Revenue
Other Countries	0.71 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Opko Health Inc's Comment on Sales, Marketing and Customers

News about Opko Health Inc Contracts

Potential Breakthrough in HIV Treatment: ModeX Trispecific Antibody Shows Promising Safety and Efficacy Results in Phase 1 Study

is pleased to present an article summarizing the recent findings from an AIDS Clinical Trial Group s Phase 1 study on ModeX Trispecific Antibody, a potential game-changer in the treatment and prevention of HIV. This significant study has highlighted the safety, pharmacokinetic profile, and potential benefits of using multispecific antibodies in humans. The following article will outline the key facts and assess their impact on the company.Factual Summary:The Phase 1 study conducted by the AIDS Clinical Trial Group represents a crucial milestone in HIV research. ModeX Trispecific Antibody, a groundbreaking candidate, has demonstrated promising results as a potential treatment modality for HIV. The study prov...

OPK's Stock Performance relative to it's Customers

OPK's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Opko Health Inc	1,155.56	581.12	-212.92	2,275
SUBTOTAL	0.00	0.00	0.00	-

Sources: Opko Health Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Opko Health Inc’s corporate clients.
For your research, we’ve provided 9 tables on Opko Health Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.